

ADNI PPSB Update

ADNI Steering Committee Meeting
18 April, 2016



Congratulations to Mike and core leadership on the outstanding review of the ADNI3 application

PPSB Spring Face to Face Meeting

17 April 2016

- Andy Saykin & Wade Davis: DNA methylation study
- John Morris: DIAN-ADNI comparison study
- Update from the CEWG
 - Collaboration in development of R package for analysis of private data in common format
 - Financial Capacity Instrument
 - Cogstate
- PET Core update from Bill Jagust
- Focus on 2 issues of keen interest:
 - Implementation of tau PET in ADNI3
 - Discovery and further development of CSF biomarkers

All ADNI3 subjects will get longitudinal tau PET

- AV1451 ready to go, but experience with another tracer desirable
- 6 companies presented to Tau PET EWG (29 February):
 - AVID, GE, Genentech, Merck, Piramal, Roche
 - Scientific and logistical challenges to be solved
- Factors militate against introduction of another tracer
 - All rollovers scanned in Y1; all new subjects scanned within 2y
 - All followup scans with the same tracer
- Open data access is what makes experience with a 2nd tracer in ADNI valuable
- Tau tracer committee: Chet Mathis, Bill Jagust, Eric Reiman, & 2 PPSB members

BBWG: further use of CSF

- Analysis of all ADNI CSF samples for A β 42, tau, and p-tau by Roche Elecsys in 3Q16
- Can further development of new/improved platforms for A β 42 be supported?
 - Remnants or new aliquots?
 - Prioritize novel biomarkers over incremental improvements in A β assays?
- Process:
 - Application through RARC
 - Final decision by NIA

Blood based biomarker deep dive

- Organized by Johan Luthman
- 11 companies participated
- An intense afternoon!